We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Four years on, the Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s disease, simufilam, proving to be nothing more ...

Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation. As the company prepares to release trial results, Ben Hargreaves finds that ...

Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam. The bull thesis hinges on simufilam outperforming current treatments or ...

Cassava Sciences (SAVA) shares are cratering by over 80% on Monday after the pharmaceutical company failed to meet its latest phase three trial goals on its Alzheimer's treatment drug, simufilam.

Cassava Sciences, Inc. (SAVA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

MANILA, Philippines — The Department of Agriculture (DA) targets to make the country’s self sufficiency in corn and cassava hit 81 percent next year on the back of a P5.3 billion program aimed ...

Cassava Sciences ( (SAVA)) has released its Q3 earnings. Here is a breakdown of the information Cassava Sciences presented to its investors. Cassava Sciences, Inc., a clinical-stage biotechnology ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end. The Austin, Texas-based biotech revealed that simufilam failed its ...

Cassava flour, Salt, Palm oil, Peppers, Onions, Seasoning and spices ...

Cassava Sciences' stock has declined significantly since its peak, with ongoing skepticism about the efficacy of its Alzheimer's drug, simufilam. Phase 3 trial results for simufilam are ...